CFO SpotlightsCareers of chief financial officers, from the filings. Records as of October 28, 2026
  1. CFO Spotlights
  2. Profiles
  3. Geoffrey Parker

Profile

Geoffrey Parker

Chief Financial Officer ( Principal Financial Officer ), Allogene Therapeutics, Inc.

Leaving, effective November 6, 2026. First published here October 28, 2026; built from records as of October 28, 2026.

Geoffrey Parker is leaving the chief financial officer seat at Allogene Therapeutics, Inc.: the company's filing of September 2, 2026 gives November 6, 2026 as the effective date.2

Seats

The seat in the record

CompanyTitle as filedStandingFilings
Allogene Therapeutics, Inc. (ALLO)
Biological Products, (No Diagnostic Substances)
Chief Financial Officer ( Principal Financial Officer )Leaving, effective November 6, 20262

Company names link to the company's page in the record at CFO Tribune, which holds the seat history.

The record

Filing by filing, latest first

  1. November 6, 2026takes effect

    Allogene Therapeutics, Inc. reported the departure of Geoffrey Parker from the chief financial officer seat, effective November 6, 2026.

    On August 31, 2026, Geoffrey Parker, the Executive Vice President and Chief Financial Officer and principal financial officer of Allogene Therapeutics, Inc. (the “Company”), provided notice of his retirement from the Company in all capacities, effective November 6, 2026.

    [2] Filing by Allogene Therapeutics, Inc., filed with the SEC on September 2, 2026. Read the filing. The record at CFO Tribune.

  2. March 12, 202610-K filed

    Geoffrey Parker signed the annual report of Allogene Therapeutics, Inc. on Form 10-K as Chief Financial Officer ( Principal Financial Officer ), filed March 12, 2026.

    /s/ Geoffrey Parker Chief Financial Officer March 12, 2026 Geoffrey Parker ( Principal Financial Officer )

    [1] Annual report on Form 10-K by Allogene Therapeutics, Inc., filed with the SEC on March 12, 2026. Read the filing. The record at CFO Tribune.

Sources

Sources

  1. Annual report on Form 10-K, Allogene Therapeutics, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed March 12, 2026. sec.gov; record.
  2. Current report filed with the SEC, Allogene Therapeutics, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed September 2, 2026. sec.gov; record.

Corrections and removal

If a line here is wrong, or Geoffrey Parker wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.